Transcept Pharmaceuticals, Inc. (TSPT) Reports Q1 EPS Loss of $0.14, Tops Consensus by $0.13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts TSPT Hot Sheet
Join SI Premium – FREE
Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT) reported Q1 EPS of ($0.14), $0.13 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $3.1 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Oil-Dri Corp. (ODC) Reports Q4 EPS of $1.00
- Delta Air Lines Q3 earnings preview: stronger print expected, fuel impact in focus
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
